Compare iShares MSCI China ETF (MCHI) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? iShares MSCI China ETF trades at $52.46 (market cap $5.94B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.69 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 4.3× iShares MSCI China ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| MCHI | RPRX | |
|---|---|---|
Market Cap | $5.94B | $25.27B |
Volume | 1,575,471 | 3,671,183 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $63.96 |
52-Week Low | $50.48 | $35.44 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $52.45, up 1.57% with a bearish technical outlook as moving averages signal strong selling pressure. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights mixed signals with corporate profits surging 26% in Q2 2026 while exports face global pushback. Institutional activity shows conflicting positions with Empowered Funds acquiring shares while Acima Private Wealth reduced holdings.
The outlook remains cautious given China's macroeconomic pressures and trade tensions. Investment opportunity exists in the significant discount to historical valuations, but risks include potential export controls, protectionism threats, and ongoing economic rebalancing challenges that could pressure Chinese equities.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
